Open AccessSystematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis
Author(s) -
Pooja Raina,
Somnath Basu,
Ramesh K. Goyal,
PK Sahoo,
Rajani Mathur
Publication year - 2022
Publication title -
journal of pharmacology and pharmacotherapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.301
H-Index - 34
eISSN - 0976-5018
pISSN - 0976-500X
DOI - 10.1177/0976500x221080225
Subject(s) - ocrelizumab , medicine , natalizumab , alemtuzumab , multiple sclerosis , adverse effect , rituximab , immunology , transplantation , lymphoma